OncoMatch/Clinical Trials/NCT07084662
Xinlikang Capsule for Chemotherapy-induced Fatigue and Immune Disorders in Diffuse Large B Lymphoma
Is NCT07084662 recruiting? Yes, currently enrolling (May 2026). This Phase 2/3 trial studies multiple treatments including Xinlikang capsules and mimic capsules for diffuse large b-cell lymphoma (dlbcl).
Treatment: Xinlikang capsules · mimic capsules — To evaluate the efficacy and safety of Xinlikang capsule in the treatment of cancer-related fatigue (CRF) and peripheral blood lymphocytes in patients with diffuse large B-cell lymphoma (DLBCL) who achieved complete remission (CR) after all courses of chemotherapy-containing regimens
Check if I qualifyExtracted eligibility criteria
Cancer type
Diffuse Large B-Cell Lymphoma
Non-Hodgkin Lymphoma
Prior therapy
Must have received: chemotherapy — first-line
Patients had completed the first-line treatment of chemotherapy and immunotherapy and the course of treatment had been completed.
Must have received: immunotherapy — first-line
Patients had completed the first-line treatment of chemotherapy and immunotherapy and the course of treatment had been completed.
Lab requirements
Blood counts
white blood cell ≤1.0×10^9/L, neutrophil ≤0.5×10^9/L, platelet ≤30×10^9/L, hemoglobin ≤6g/dL
Kidney function
BUN and Cr≥3 ULN
Liver function
ALT, AST, GGT≥3 ULN
Significant abnormal liver and kidney function: ALT, AST, GGT≥3 ULN; BUN and Cr≥3 ULN; Severe abnormal bone marrow function: white blood cell ≤1.0×10^9/L, neutrophil ≤0.5×10^9/L, platelet ≤30×10^9/L, hemoglobin ≤6g/dL
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify